{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-073986","form_type":"8-K","ticker":"ELAB","cik":"0001840563","company_name":"PMGC Holdings Inc.","filed_at":"2026-07-01T11:31:32+00:00","discovered_at":"2026-07-01T11:35:00.279338+00:00","generated_at":"2026-07-01T11:35:12.595657+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"NorthStrive Biosciences reports positive Phase III results: 4 AI-selected compounds increase ANT1 expression up to 50%","bullets":["Four AI-selected compounds (C1, C2, C3, C4) significantly increased ANT1 expression in human skeletal muscle cells.","Strongest dose-dependent induction: C2 up to +50%, C4 up to +48%, C1 up to +46%, C3 +29% at highest dose.","Yuva Biosciences recommended advancing the four candidates into a more mature muscle model for confirmatory testing.","Results validate MitoNova AI platform's ability to identify biologically active small-molecule candidates."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-073986","json":"https://secwatch.observer/filing/0001213900-26-073986.json","markdown":"https://secwatch.observer/filing/0001213900-26-073986.md","text":"https://secwatch.observer/filing/0001213900-26-073986.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840563/000121390026073986/0001213900-26-073986-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840563/000121390026073986/ea0296527-8k_pmgc.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-01T11:35:12.595657+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}